📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 08:55
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
28 announcements match the current filters (relevance ≥ 5).
CARE Reaffirms SMS Pharma at 'CARE A/A1'; Revises Long-Term Outlook to 'Stable' from 'Positive'
CARE Ratings has reaffirmed SMS Pharmaceuticals' long-term bank facilities rating at 'CARE A' and short-term facilities at 'CARE A1'. The outlook on long-term facilities has been revised from 'Positive' to 'Stable', while the rated long-term amount was enhanced to ₹570.07 crore from ₹350.87 crore. Total bank facilities rated stand at ₹622.90 crore, including ₹349.07 crore in term loans primarily to support capex programs.
Confidence: HIGH
What changedCARE Ratings reaffirmed ratings but moderated the long-term outlook from 'Positive' to 'Stable' while expanding rated long-term limits by ₹219.20 crore.
Why it mattersThe revision to a 'Stable' outlook indicates credit metrics are expected to hold steady rather than upgrade near-term, reflecting higher debt utilization for ongoing capex against a current total debt of ₹365 crore.
Long-term rated facilities: ₹570.07 crorePrevious long-term limit: ₹350.87 croreShort-term rated facilities: ₹52.83 croreTotal rated bank facilities: ₹622.90 croreTotal rated facilities vs TTM revenue: ~69.4%
📅 Short termNeutral sentiment; credit profile remains investment grade 'A' category with sufficient liquidity headroom across sanctioned limits.
📈 Long termReflects execution and funding of capital expansion projects, with stable rating profiles ensuring continuous access to bank financing at standard borrowing costs.
⚠ Risk flags
- Increased leverage from debt-funded capex facilities
- Outlook moderated from Positive to Stable
Key Highlights
Long-term bank facilities rating reaffirmed at 'CARE A', with outlook revised from 'Positive' to 'Stable'
Long-term rated facility size increased to ₹570.07 crore from ₹350.87 crore
Short-term bank facilities rating reaffirmed at 'CARE A1' for ₹52.83 crore
Total rated bank facilities increased to ₹622.90 crore (covering ₹349.07 crore term loans and ₹221.00 crore fund-based limits)
👀 What to Watch
Track the commissioning and cash flow generation from the ₹280 crore backward integration project to see if debt levels normalize and return ratios expand.
SMSPHARMA Q1 Revenue at ₹207 Cr; ₹280 Cr Capex and ₹50 Cr Peptide Infusion Underway
SMS Pharmaceuticals reported a steady Q1FY27 with revenue growing 6% YoY to ₹207 crore and PAT increasing 8% to ₹20 crore. The company is aggressively pursuing a ₹280 crore capex program (representing ~32% of TTM revenue) to be completed by FY27, focusing on capacity expansion and new products. A strategic infusion of ₹50 crore as a loan into SMS Peptides Private Limited highlights a shift toward high-margin R&D. High-value products now contribute 51% of total revenue, helping sustain EBITDA margins at 20%.
Confidence: HIGH
What changedThe company has formalized a ₹50 crore funding plan for its peptide subsidiary and reached a milestone where high-value products constitute over half of its revenue mix.
Why it mattersThe shift toward peptides and high-value APIs, supported by significant capex, is designed to protect margins against generic price erosion and diversify the therapeutic portfolio.
Q1FY27 Revenue: ₹207 crCapex Program Value: ₹280 crCapex vs TTM Revenue: 31.6%Peptide Subsidiary Loan: ₹50 crHigh-Value Product Share: 51%Target Asset Turnover: 1.75x
📅 Short termThe stock may see positive sentiment due to stable 20% EBITDA margins and clear visibility on the peptide segment funding.
📈 Long termStructural growth depends on the successful execution of the ₹280 cr capex and the ability to scale the peptide business to improve return ratios (ROCE currently at 13%).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High client concentration (Top 5 customers at 56% of FY24 revenue)
- Regulatory risk with 88% revenue from regulated markets
- Execution risk of large-scale capex
Key Highlights
Q1FY27 Revenue grew 6% YoY to ₹207 crore, while PAT rose 8% to ₹20 crore.
Ongoing ₹280 crore capex program is on track for FY27 completion, targeting a net asset turnover of 1.75x.
Board approved a ₹50 crore loan infusion into subsidiary SMS Peptides to establish a dedicated R&D facility.
High-value product share increased to 51% in Q1FY27, up from 47% in FY26.
Completed 4 DMF/CEP filings in Q1, tracking toward a full-year target of 10 filings.
👀 What to Watch
Investors should monitor the progress of the ₹280 crore capex completion and the commercialization timeline of the peptide R&D facility, which are critical for achieving the 1.75x asset turnover target.
SMSPHARMA Q1 FY27: 6% Revenue Growth to ₹207 Cr; ₹160 Cr Remaining Capex on Track
SMS Pharmaceuticals reported a steady Q1 FY27 with revenue growing 6% YoY to ₹207.0 Cr and PAT increasing 8% to ₹20.20 Cr. Gross margins expanded by 217 bps to 36% due to backward integration, though EBITDA margins remained flat at 20% due to higher freight and employee costs. The company is progressing on its ₹280 Cr capex plan, with ₹160 Cr (approx. 18% of TTM revenue) remaining to be spent by FY27. Additionally, the board approved a ₹50 Cr loan to its peptide subsidiary to bolster its R&D capabilities.
Confidence: HIGH
What changedThe company has transitioned into the execution phase of its ₹280 Cr capex while shifting its product mix heavily toward ARV and Anti-migraine APIs to offset a sharp decline in Anti-diabetic revenue.
Why it mattersThe sustained 20% EBITDA margin despite cost headwinds suggests improved operational resilience from backward integration. The ₹50 Cr loan to the peptide subsidiary indicates a strategic push into high-value, complex therapeutic areas.
Q1 FY27 Revenue: ₹207.0 CrPAT Growth (YoY): 8%Remaining Capex: ₹160 CrRemaining Capex vs TTM Revenue: 18.03%Subsidiary Loan Approval: ₹50 CrEBITDA Margin: 20%
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the 13% QoQ revenue decline and the sharp drop in the anti-diabetic segment, despite YoY growth.
📈 Long termLong-term value depends on the successful commissioning of the remaining ₹160 Cr capex and the ability to scale the peptide R&D facility into a meaningful CDMO contributor by FY27.
⚠ Risk flags
- High client concentration (Top 5 customers = 56% of revenue)
- Geopolitical risks impacting freight costs
- Significant volatility in the Anti-diabetic therapeutic segment
Key Highlights
Revenue increased 6% YoY to ₹207.0 Cr, supported by a 69% growth in the Anti-Retro Viral (ARV) segment.
Gross margin improved to 36% from 34% YoY, reflecting structural benefits from backward integration.
Remaining capex of ₹160 Cr is scheduled for completion by FY27 to support new niche molecule launches.
Board approved a ₹50 Cr loan to subsidiary SMS Peptides Private Limited for its dedicated R&D facility.
Anti-diabetic segment revenue saw a significant 69% YoY decline, dropping to ₹20.08 Cr from ₹65.16 Cr.
👀 What to Watch
Investors should monitor the commercialization timeline of the 6-8 niche molecules expected by the end of FY27 and the impact of the ₹50 Cr peptide investment on future CDMO revenue. Watch for margin recovery if geopolitical freight pressures ease as management anticipates.
SMSPHARMA Q1 Revenue Grows 5.6% to ₹207 Cr; ₹50 Cr Loan to Subsidiary Approved
SMS Pharmaceuticals reported a steady Q1 FY27 with consolidated revenue rising 5.6% YoY to ₹206.96 Cr. Consolidated Profit Before Tax (PBT) increased by 11.6% YoY to ₹27.20 Cr, showing improved operational efficiency. The Board approved a ₹50 Cr unsecured loan to its 99.99% subsidiary, SMS Peptides, which represents approximately 6.2% of the company's net worth. Additionally, the Chairman and Managing Director was re-appointed for a five-year term, ensuring leadership continuity through 2031.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27 and committed ₹50 Cr in funding to its peptide subsidiary while securing leadership for the next five years.
Why it mattersThe steady earnings growth confirms the stability of the core API business, while the loan to the peptide subsidiary indicates a strategic diversification into higher-value segments.
Q1 Consolidated Revenue: ₹206.96 CrQ1 Consolidated PBT: ₹27.20 CrLoan to Subsidiary: ₹50 CrLoan vs Net Worth: 6.2%Dividend Record Date: September 16, 2026
📅 Short termThe stock is likely to remain stable as the earnings growth is modest and in line with expectations, with the subsidiary loan being a standard internal funding move.
📈 Long termLong-term value depends on the successful execution of the ₹280 Cr backward integration project and the scaling of the peptide business to diversify from commoditized APIs.
⚠ Risk flags
- Related-party transaction (₹50 Cr loan to subsidiary)
- High client concentration (Top 5 customers contribute 56% of revenue)
- Regulatory risk (88% of revenue from regulated markets)
Key Highlights
Consolidated Revenue from Operations reached ₹206.96 Cr, up from ₹196.05 Cr in the same quarter last year.
Consolidated Profit Before Tax (PBT) grew to ₹27.20 Cr, an 11.6% increase over the ₹24.37 Cr reported in Q1 FY26.
Approved an unsecured loan of up to ₹50 Cr to subsidiary SMS Peptides Private Limited for business purposes.
Re-appointed Mr. Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term effective October 1, 2026.
Fixed September 16, 2026, as the record date for the final dividend for the financial year 2025-26.
👀 What to Watch
Investors should monitor the performance of the new peptide subsidiary and the progress of the ₹280 Cr backward integration project intended to boost margins.
SMSPHARMA Q1 Profit Up 16% to ₹21.13 Cr; ₹50 Cr Loan to Subsidiary Approved
SMS Pharmaceuticals reported a steady Q1 FY27 with consolidated net profit rising 16% YoY to ₹21.13 Cr. Revenue from operations grew 5.6% YoY to ₹206.96 Cr, though it saw a sequential decline from Q4 FY26. The board approved a significant unsecured loan of up to ₹50 Cr to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. Additionally, the company fixed September 16, 2026, as the record date for the FY26 dividend and re-appointed its CMD for a five-year term.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, established a dividend record date, and committed ₹50 Cr in capital to a subsidiary.
Why it mattersThe earnings show continued growth in the API business, while the loan to the peptide subsidiary indicates a strategic push into new therapeutic segments.
Q1 Net Profit: ₹21.13 CrQ1 Revenue: ₹206.96 CrLoan to Subsidiary: ₹50 CrLoan vs Net Worth: ~6.2%Dividend Record Date: 16-Sep-2026
📅 Short termThe stock may react positively to the 16% profit growth and the clarity provided on the dividend record date.
📈 Long termLeadership continuity for five years and expansion into the peptide segment through the subsidiary are structural positives for long-term growth.
⚠ Risk flags
- Related-party transaction (₹50 Cr loan to subsidiary)
- High client concentration (top 5 customers at 56%)
Key Highlights
Consolidated Net Profit increased 16% YoY to ₹21.13 Cr for the quarter ended June 30, 2026.
Revenue from operations stood at ₹206.96 Cr, up from ₹196.05 Cr in the same quarter last year.
Approved an unsecured loan of up to ₹50 Cr to subsidiary SMS Peptides Private Limited for business purposes.
Fixed September 16, 2026, as the Record Date for determining dividend eligibility for FY 2025-26.
Re-appointed Mr. Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term until September 2031.
👀 What to Watch
Investors should monitor the performance of the new subsidiary, SMS Peptides, and the utilization of the ₹50 Cr loan, alongside the progress of the ongoing ₹280 Cr backward integration project.
Rs 21.13 Cr Q1 PAT: SMSPHARMA Reports 16% YoY Profit Growth; MD Re-appointed for 5 Years
SMS Pharmaceuticals reported a steady Q1 FY27 with standalone PAT rising 16% YoY to Rs 21.13 Cr, despite a modest 5.6% growth in revenue to Rs 206.96 Cr. The Board approved the re-appointment of promoter Ramesh Babu Potluri as Chairman and MD for a five-year term starting October 2026, ensuring leadership continuity. Additionally, the company authorized a loan of up to Rs 50 Cr to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. A record date of September 16, 2026, has been set for the FY26 dividend payment.
Confidence: HIGH
What changedThe company has secured leadership for the next five years and initiated a significant capital allocation (Rs 50 Cr loan) to its peptide-focused subsidiary.
Why it mattersThe 16% profit growth on 5.6% revenue growth indicates improved operational efficiency or a better product mix. The loan to the peptide subsidiary signals a strategic move into higher-value niche segments.
Q1 Standalone PAT: Rs 21.13 CrQ1 Revenue: Rs 206.96 CrLoan to Subsidiary: Rs 50 CrLoan vs Net Worth: ~6.2%Dividend Record Date: September 16, 2026
📅 Short termThe stock may see positive sentiment due to the double-digit profit growth and the upcoming dividend record date.
📈 Long termLeadership continuity and the expansion into peptides provide structural stability, though high client concentration (top 5 = 56%) remains a long-term monitorable.
⚠ Risk flags
- Related-party transaction (Rs 50 Cr loan to subsidiary)
- High client concentration
- Regulatory risks in 75+ export markets
Key Highlights
Standalone Net Profit grew 16% YoY to Rs 21.13 Cr in Q1 FY27 compared to Rs 18.21 Cr in Q1 FY26
Revenue from operations increased 5.6% YoY to Rs 206.96 Cr from Rs 196.05 Cr
Approved an unsecured loan of up to Rs 50 Cr to subsidiary SMS Peptides Private Limited for business purposes
Re-appointed Mr. Ramesh Babu Potluri as MD for a 5-year term effective October 1, 2026, to September 30, 2031
Fixed September 16, 2026, as the Record Date for determining dividend eligibility for FY 2025-26
👀 What to Watch
Investors should monitor the progress of the Rs 280 Cr backward integration project mentioned in company strategy and the operational ramp-up of the new peptide subsidiary.
SMSPHARMA Q1 Net Profit Up 16% YoY to ₹21.1 Cr; ₹50 Cr Loan to Subsidiary Approved
SMS Pharmaceuticals reported a steady Q1 FY27 with standalone net profit rising 16% YoY to ₹21.13 crore, despite a 13% sequential revenue decline to ₹206.96 crore. The board approved a ₹50 crore unsecured loan to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. Additionally, CMD Ramesh Babu Potluri was re-appointed for a five-year term, and September 16, 2026, was fixed as the record date for the FY26 dividend.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results showing stable YoY growth, initiated funding for a new peptide subsidiary, and confirmed leadership continuity for the next five years.
Why it mattersThe results show the company is maintaining profitability despite sequential revenue volatility; the loan to the subsidiary indicates a strategic diversification into the peptide segment.
Standalone Net Profit (Q1): ₹21.13 crRevenue Growth (YoY): 5.5%Loan to Subsidiary: ₹50 crLoan vs Net Worth: ~6.2%Dividend Record Date: 16th September 2026
📅 Short termThe stock may see neutral to slightly positive movement as the market digests steady YoY profit growth and the dividend record date announcement.
📈 Long termLong-term value depends on the successful ramp-up of the peptide subsidiary and the completion of the ₹280 crore capex to support 8-10 new product launches.
⚠ Risk flags
- Related-party transaction (₹50 cr loan to subsidiary)
- High client concentration (top 5 customers = 56% of revenue)
- Sequential revenue decline of 13% compared to Q4 FY26
Key Highlights
Standalone Net Profit grew 16% YoY to ₹21.13 crore for the quarter ended June 30, 2026
Consolidated Revenue from Operations stood at ₹206.96 crore, a 5.5% increase over Q1 FY26
Approved an unsecured loan of up to ₹50 crore to subsidiary SMS Peptides Private Limited for business purposes
Re-appointed Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term starting October 1, 2026
Fixed September 16, 2026, as the record date for determining dividend eligibility for FY26
👀 What to Watch
Monitor the utilization of the ₹50 crore loan by the new subsidiary (SMS Peptides) and the execution of the ₹280 crore backward integration project to see if it drives the targeted margin expansion.
SMSPHARMA Q1 PAT Rises 11% YoY to ₹20.2 Cr; Board Approves ₹50 Cr Loan to Subsidiary
SMS Pharmaceuticals reported a consolidated revenue of ₹206.96 Cr for Q1 FY27, reflecting a 5.6% YoY growth but a 13% sequential decline from Q4 FY26. Consolidated Net Profit grew 10.9% YoY to ₹20.20 Cr, driven by improved operational efficiencies despite a rise in employee benefit expenses to ₹23.54 Cr. The board approved a ₹50 Cr unsecured loan to its 99.99% subsidiary, SMS Peptides Private Limited, for business purposes, representing approximately 6.2% of the company's net worth. Additionally, the company confirmed the re-appointment of CMD Ramesh Babu Potluri for a five-year term starting October 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, secured leadership continuity for the next five years, and initiated financial support for its peptide subsidiary.
Why it mattersWhile YoY growth remains positive, the sequential dip in revenue and the ₹50 Cr capital allocation to a subsidiary indicate a transition phase as the company diversifies into new therapeutic areas like peptides.
Consolidated Revenue (Q1 FY27): ₹206.96 CrConsolidated PAT (Q1 FY27): ₹20.20 CrLoan to Subsidiary: ₹50 CrLoan vs Net Worth: ~6.2%YoY Revenue Growth: 5.6%QoQ Revenue Growth: -13.0%
📅 Short termThe stock may see neutral to slightly cautious movement due to the sequential revenue decline, despite the YoY profit growth.
📈 Long termLong-term prospects depend on the successful ramp-up of the peptide business and the margin benefits from the ongoing backward integration project.
⚠ Risk flags
- High client concentration (Top 5 customers = 56% of revenue)
- Sequential revenue decline of 13%
- Execution risk in the new peptide subsidiary
Key Highlights
Consolidated Revenue from Operations reached ₹206.96 Cr in Q1 FY27 compared to ₹196.05 Cr in Q1 FY26.
Consolidated Net Profit for the quarter stood at ₹20.20 Cr, up from ₹18.21 Cr in the same period last year.
Approved an unsecured loan of up to ₹50 Cr to subsidiary SMS Peptides Private Limited in one or more tranches.
Re-appointed Mr. Ramesh Babu Potluri as Chairman and Managing Director for a 5-year term effective October 1, 2026.
Fixed September 16, 2026, as the Record Date for the dividend for FY 2025-26.
👀 What to Watch
Investors should monitor the performance of the new peptide subsidiary and the execution of the ₹280 Cr backward integration project to see if it offsets the 13% sequential revenue decline.
SMS Pharma Reports Fraudulent Claim of 85,000 Equity Shares; Files EOW Complaint
SMS Pharmaceuticals has uncovered a fraudulent scheme involving the illegal claim of 85,000 equity shares by impersonators. The fraud affected 7 original shareholders who held shares in physical form and was discovered during a routine KYC update process. The company has proactively filed a formal complaint with the Economic Offences Wing (EOW), Hyderabad, to protect shareholder interests. While the company is taking legal action, this incident highlights risks associated with physical share certificates.
Key Highlights
Identification of fraudulent claims involving 85,000 equity shares in physical form.
A total of 7 original shareholders were targeted using forged and fabricated documents.
Company filed a suo motu complaint with the Economic Offences Wing (EOW), Hyderabad, which has registered a case.
The fraud involved a common modus operandi with impersonated claimants using identical or nearby addresses.
👀 What to Watch
Investors still holding physical share certificates should prioritize dematerializing their holdings to prevent impersonation and fraud. Monitor for further updates from the EOW investigation regarding potential systemic lapses or further discoveries.
SMS Pharma FY26 PAT Jumps 47% to ₹102 Cr; Targets 22% EBITDA Margin in FY27
SMS Pharmaceuticals reported a strong FY26 with revenue growing 13% to ₹887 crores and PAT surging 47% to ₹102 crores, aided by a ₹14 crore contribution from associate VKT Pharma. The company successfully expanded its EBITDA margin to 20% through backward integration in key products like Ibuprofen. Management has guided for a 15% revenue growth in FY27 and aims for a record 22% EBITDA margin despite geopolitical logistics challenges. A ₹280 crore brownfield expansion is underway to increase Ibuprofen capacity to 800 MT/month and launch high-margin APIs.
Key Highlights
FY26 PAT increased by 47% YoY to ₹102 crores, while EBITDA grew 23% to ₹171 crores.
Ibuprofen capacity is being expanded from 500 MT to 800 MT per month, with completion expected by March 2027.
Management targets a historical high EBITDA margin of 22% for FY27, up from 20% in FY26.
Filed 12 DMFs/CEPs in FY26 with plans for 10 more in FY27 to diversify the product portfolio.
Invested ₹130 crores out of a planned ₹280 crores capex for brownfield expansion and backward integration.
👀 What to Watch
Investors should monitor the progress of the Ibuprofen capacity expansion and the stabilization of solvent costs, which impacted Q4 margins. The stock remains attractive due to strong backward integration and a clear roadmap for high-margin API launches in FY28.
SMSPHARMA FY26 PAT Surges 47% to ₹102 Cr; EBITDA Margins Expand to 19%
SMS Pharmaceuticals reported a strong performance for FY26, with consolidated PAT growing 47% YoY to ₹102 crore, significantly aided by the share of profit from its associate, VKT Pharma. Annual revenue increased by 13% to ₹887 crore, while EBITDA margins expanded by 155 bps to 19% due to strategic backward integration and an improved product mix. The company is currently executing a ₹280 crore Capex plan scheduled for completion by FY27 to drive future capacity. Additionally, the Board has recommended a final dividend of ₹0.40 per share.
Key Highlights
FY26 PAT increased by 47% YoY to ₹102 crore, with EPS rising 37% to ₹11.15.
EBITDA margins improved to 19% in FY26, driven by backward integration and a 47% share of high-value products.
Revenue from operations grew 13% YoY to ₹887 crore, despite a slight 4% YoY dip in Q4 revenue to ₹238 crore.
A ₹280 crore Capex program is on track for completion by FY27, focusing on brownfield and greenfield expansions.
The Board recommended a final dividend of ₹0.40 (40%) per equity share for the fiscal year.
👀 What to Watch
Investors should view the strong margin expansion and the successful contribution from VKT Pharma as positive indicators of operational efficiency. The ongoing Capex and target to double R&D investment suggest a robust growth pipeline, making it a stock to hold for long-term value.
SMSPHARMA FY26 PAT Jumps 48% to ₹102 Cr; Recommends ₹0.40 Dividend
SMS Pharmaceuticals reported a strong FY26 performance with PAT growing 48% YoY to ₹101.98 crore, bolstered by a ₹14 crore contribution from its associate, VKT Pharma. Annual revenue increased by 13% to ₹886.87 crore, driven by significant growth in Anti-Retro Viral (55%) and Anti-epileptic (85%) segments. EBITDA margins expanded by 155 basis points to 19% for the full year, attributed to successful backward integration and a strategic shift in product mix. The company provided optimistic guidance for FY27, targeting over 15% revenue growth and 20% EBITDA margins.
Key Highlights
Full-year PAT increased 48% YoY to ₹102 crore, with FY26 EBITDA margins rising 155 bps to 19%.
Revenue from Anti-Retro Viral (ARV) APIs surged 55% YoY to ₹251.80 crore, now representing 28% of total revenue.
The Board recommended a final dividend of ₹0.40 per share (40% of face value).
A ₹280 crore Capex program is on track for FY27 completion to enhance R&D and manufacturing capacity.
Management guidance for FY27 includes >15% revenue growth and EBITDA margins around 20%.
👀 What to Watch
Investors should focus on the successful margin expansion through backward integration and the strong FY27 guidance. The stock remains attractive for long-term investors given the ongoing ₹280 crore capacity expansion and diversifying product portfolio.
SMS Pharma FY26 Net Profit Rises 28% to ₹87.6 Cr; Recommends ₹0.40 Dividend
SMS Pharmaceuticals reported a strong full-year performance for FY26, with net profit growing 28.1% YoY to ₹87.61 crore. Annual revenue from operations increased by 13.3% to ₹886.87 crore, although Q4 revenue saw a slight year-on-year dip. The board has recommended a final dividend of ₹0.40 per share. Additionally, the company strengthened its capital base by converting 50 lakh warrants into equity shares, raising approximately ₹47.6 crore.
Key Highlights
Full-year FY26 Net Profit grew 28.1% to ₹8,760.93 lakhs compared to ₹6,838.12 lakhs in FY25.
Annual Revenue from Operations increased 13.3% to ₹88,687.10 lakhs from ₹78,274.81 lakhs.
Recommended a final dividend of ₹0.40 per equity share (40% of face value) for FY26.
Converted 50,00,000 warrants into equity shares, increasing paid-up capital to ₹936.52 lakhs.
Approved shifting the registered office to Kondapur, Hyderabad, effective May 25, 2026.
👀 What to Watch
Investors should view the robust annual profit growth and dividend declaration as positive signs of operational efficiency. Monitor the impact of the equity dilution from warrant conversion on future EPS.
SMSPHARMA FY26 Net Profit Rises 28% to ₹87.6 Cr; Declares ₹0.40 Dividend
SMS Pharmaceuticals reported a strong performance for FY26, with annual revenue growing 13.3% YoY to ₹886.87 crore. Net profit surged by 28% to reach ₹87.61 crore, driven by improved operational efficiencies and higher volumes. The company declared a final dividend of ₹0.40 per share (40% of face value). Additionally, the company successfully converted 50 lakh warrants into equity, raising ₹47.62 crore to strengthen its capital base.
Key Highlights
Annual Revenue from Operations increased 13.3% to ₹88,687.10 Lakhs in FY26 vs ₹78,274.81 Lakhs in FY25.
Net Profit for the full year grew by 28% to ₹8,760.93 Lakhs compared to ₹6,838.12 Lakhs in the previous fiscal.
Board recommended a final dividend of ₹0.40 per equity share (40%) for the financial year 2025-26.
Converted 50,00,000 warrants into equity shares, resulting in a fund infusion of ₹4,762.50 Lakhs.
Full-year Basic EPS improved to ₹9.58 from ₹8.07 in FY25, despite equity dilution from warrant conversion.
👀 What to Watch
The strong bottom-line growth and consistent dividend payout reflect healthy financial performance. Investors should maintain a positive outlook while monitoring the utilization of newly raised capital for future expansion.
SMSPHARMA FY26 Net Profit Rises 28% to ₹87.6 Cr; Recommends ₹0.40 Dividend
SMS Pharmaceuticals reported a strong full-year performance for FY26, with consolidated net profit growing 28.1% year-on-year to ₹87.61 crore. Annual revenue from operations increased by 13.3% to reach ₹886.87 crore, driven by its core API manufacturing business. The Board has recommended a final dividend of ₹0.40 per equity share (40% of face value). While annual figures were robust, Q4 revenue saw a marginal decline to ₹237.95 crore compared to ₹248.20 crore in the previous year's quarter.
Key Highlights
Annual Net Profit increased by 28.1% YoY to ₹8,760.93 Lakhs in FY26.
Full-year Revenue from Operations grew 13.3% to ₹88,687.10 Lakhs.
Recommended a final dividend of ₹0.40 per equity share (40% of face value) for FY25-26.
Successfully converted 50,00,000 warrants into equity shares, raising ₹4,762.50 Lakhs.
Statutory auditors issued an 'Unmodified Opinion' on both standalone and consolidated financial statements.
👀 What to Watch
Investors should take note of the strong annual profit growth and consistent dividend payout, though the flat Q4 performance suggests monitoring quarterly momentum is necessary.
SMS Pharma FY26 Net Profit Grows 28% to ₹87.6 Cr; ₹0.40 Dividend Recommended
SMS Pharmaceuticals reported a strong full-year performance for FY26, with standalone net profit rising 28.1% to ₹87.6 crore. Annual revenue from operations grew by 13.3% to ₹886.9 crore, driven by its core API and intermediates business. The Board has recommended a final dividend of ₹0.40 per share, representing a 40% payout on face value. Additionally, the company strengthened its capital base by converting 50 lakh warrants into equity shares during the fiscal year.
Key Highlights
Full-year Net Profit increased by 28.1% YoY to ₹8,760.93 lakhs in FY26
Annual Revenue from Operations grew 13.3% to ₹88,687.10 lakhs
Recommended a final dividend of ₹0.40 per equity share (40% of face value)
Earnings Per Share (EPS) improved significantly to ₹9.58 from ₹8.07 YoY
Converted 50,00,000 warrants into equity shares, increasing paid-up capital to ₹936.52 lakhs
👀 What to Watch
Investors should take note of the robust 28% annual profit growth and the healthy improvement in EPS. While Q4 revenue was slightly soft, the overall fiscal trajectory and dividend payout signal fundamental strength.
SMS Pharma FY26 Net Profit Grows 28% to ₹87.6 Cr; Declares ₹0.40 Dividend
SMS Pharmaceuticals reported a strong full-year performance for FY26, with standalone revenue growing 13.3% YoY to ₹886.87 crore. Net profit for the year surged by 28% to ₹87.61 crore, driven by improved operational efficiencies despite a relatively flat Q4 performance. The Board has recommended a final dividend of ₹0.40 per share (40% of face value). The company also strengthened its balance sheet by converting 50 lakh warrants into equity, raising ₹47.62 crore during the year.
Key Highlights
Full-year FY26 standalone revenue rose 13.3% YoY to ₹886.87 crore compared to ₹782.75 crore in FY25.
Annual Net Profit (PAT) grew significantly by 28% to ₹87.61 crore from ₹68.38 crore in the previous year.
Board recommended a final dividend of ₹0.40 per equity share of face value ₹1 each.
Earnings Per Share (EPS) for FY26 improved to ₹9.58, up from ₹8.07 in FY25.
Capital Work-in-Progress (CWIP) increased to ₹115.82 crore from ₹34.67 crore, indicating significant ongoing expansion.
👀 What to Watch
Investors should take note of the robust annual profit growth and the company's commitment to dividends. The substantial increase in Capital Work-in-Progress suggests future capacity expansion which could drive long-term growth.
SMS Pharma FY26 Net Profit Rises 28% to ₹87.6 Cr; Recommends ₹0.40 Dividend
SMS Pharmaceuticals reported a strong full-year performance for FY26, with standalone revenue growing 13.3% YoY to ₹886.87 crore. Net profit for the year surged by 28.1% to ₹87.61 crore, driven by improved operational efficiencies despite a slight 4% YoY dip in Q4 revenue. The company has recommended a final dividend of ₹0.40 per share (40% of face value). A significant highlight is the surge in Capital Work-in-Progress to ₹115.82 crore, indicating substantial ongoing capacity expansion.
Key Highlights
Full-year standalone revenue increased 13.3% YoY to ₹88,687.10 Lakhs.
Annual Net Profit grew by 28.1% to ₹8,760.93 Lakhs compared to ₹6,838.12 Lakhs in FY25.
Recommended a final dividend of ₹0.40 per equity share of face value ₹1/-.
Capital Work-in-Progress (CWIP) jumped 234% YoY to ₹11,582.43 Lakhs, signaling major expansion.
Converted 50,00,000 warrants into equity shares, raising ₹4,762.50 Lakhs during the financial year.
👀 What to Watch
The strong annual profit growth and aggressive capital expenditure on new projects (reflected in CWIP) suggest a positive long-term outlook. Investors should monitor the commissioning of these new capacities as they will be the primary drivers for future revenue growth.
SMS Pharma Tax Demand Slashed to ₹40.28 Lakhs from ₹7.19 Crores
SMS Pharmaceuticals Limited has received a rectification order from the Income Tax Department regarding the Assessment Year 2018-19. The order has significantly reduced the previous tax demand from ₹7.19 crores to just ₹40.28 lakhs following a rectification application filed by the company. While an appeal is still pending before the Commissioner of Income Tax (Appeals), this reduction mitigates a significant potential financial liability. Management believes there will be no material impact on the company's financial or operational activities at this stage.
Key Highlights
Tax demand for AY 2018-19 reduced by over 94% from ₹7.19 crores to ₹40.28 lakhs
Rectification order received under Section 154 of the Income-tax Act, 1961
Company has filed an appeal before the Commissioner of Income Tax (Appeals) regarding the remaining demand
Application filed to keep penalty proceedings under Section 270A in abeyance until appeal disposal
👀 What to Watch
The substantial reduction in tax liability is a positive development for the company's cash flow outlook. Investors should maintain their current positions as the remaining demand is not financially material to the company's overall operations.
SMS Pharma Receives ₹7.19 Crore Income Tax Demand for AY 2018-19
SMS Pharmaceuticals Limited has received a demand notice of ₹7.19 crores from the Income Tax Department for the Assessment Year 2018-19. The demand arises from the disallowance of deductions under Section 35 of the Income Tax Act and the addition of certain income. Additionally, the department has initiated penalty proceedings for the alleged under-reporting of income. The company is currently evaluating the order and intends to seek legal remedies through the appropriate appellate forums.
Key Highlights
Income tax demand of ₹7.19 crores raised for the Assessment Year 2018-19.
Order involves disallowance of deductions under Section 35 related to scientific research expenditure.
Penalty proceedings under Section 270A initiated for alleged under-reporting of income.
Company is reviewing the order and plans to contest it before the appropriate forum.
👀 What to Watch
Investors should monitor the progress of the company's appeal against this demand and check for any related financial provisions in upcoming quarterly results. While the demand is a potential liability, the company's intent to contest it may delay any immediate cash outflow.
